Hervé Ghesquières

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 484 citations · Full text

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais et al. · Journal of Clinical Oncology · 2014 · 399 citations · Full text

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles et al. · Blood · 2020 · 357 citations · Full text

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial

Christian Récher, Bertrand Coiffier, Corinne Haïoun et al. · The Lancet · 2011 · 356 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 305 citations · Full text

Neuro-oncology, Primary Vitreoretinal Lymphoma, Lymphoid Neoplasia +6